Takeda Narcolepsy Drug Hits US Market After Final Clearance

The narcolepsy drug Orzeyful has entered the US market, giving Takeda a new commercial opportunity in sleep disorder treatment following final regulatory clearance.

The company launched the drug after the Drug Enforcement Administration (DEA) completed its scheduling process, removing the final hurdle to commercial availability.

Orzeyful, also known as oveporexton, targets narcolepsy type 1 in adults by addressing disrupted orexin signaling, a key factor behind the condition.

The US drug launch positions Takeda in a treatment category where many patients continue to experience symptoms despite existing medicines.

Key Highlights

• Takeda launched Orzeyful for adults with narcolepsy type 1 in the US.
• The drug targets disrupted orexin signaling rather than individual symptoms.
• Takeda plans to initially reach patients who struggle with existing treatments.

Takeda Narcolepsy Drug Enters US Market After DEA Clearance

Takeda has launched its narcolepsy drug Orzeyful in the US after receiving final clearance from the Drug Enforcement Administration (DEA). The agency classified the medicine as Schedule IV, allowing the company to begin commercial distribution following FDA approval in August.

The twice-daily oral treatment targets adults with narcolepsy type 1, a neurological condition that causes excessive daytime sleepiness, sudden muscle weakness known as cataplexy, and disrupted nighttime sleep. Takeda has priced Orzeyful at USD 16,500 per 60-tablet bottle across strengths. Accredo Specialty Pharmacy will handle prescriptions, marking the beginning of the company's US drug launch.

Also Read: Why Global Pharma is Moving to India: The 2026 India CDMO Boom and Market Outlook

Takeda Narcolepsy Drug Targets Underlying Orexin Deficiency

Unlike conventional medicines that primarily manage symptoms, Orzeyful targets the underlying cause of narcolepsy type 1. The narcolepsy drug activates orexin receptor 2, helping restore disrupted orexin signaling that regulates wakefulness and sleep.

Takeda plans to initially focus on adults who continue experiencing symptoms despite existing narcolepsy treatment or multiple medications. The company estimates that approximately 120,000 people in the US live with narcolepsy type 1, while nearly half remain undiagnosed.

This patient population presents an opportunity for Takeda to expand access to a different treatment approach. The launch also strengthens Takeda US market presence in neurological medicines, opening a new commercial opportunity in sleep disorder care.